Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1254659

Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature


Matošević, Matija; Kos, Ivanka; Davidović, Maša; Ban, Maja; Matković, Hana; Jakopčić, Ivan; Vuković Brinar, Ivana; Szilágyi, Agnes; Csuka, Dorottya; Sinkovits, György et al.
Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature // Frontiers in pediatrics, 11 (2023), 1092860, 8 doi:10.3389/fped.2023.1092860 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1254659 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature

Autori
Matošević, Matija ; Kos, Ivanka ; Davidović, Maša ; Ban, Maja ; Matković, Hana ; Jakopčić, Ivan ; Vuković Brinar, Ivana ; Szilágyi, Agnes ; Csuka, Dorottya ; Sinkovits, György ; Prohászka, Zoltán ; Vrljičak, Kristina ; Lamot, Lovro

Izvornik
Frontiers in pediatrics (2296-2360) 11 (2023); 1092860, 8

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Haemolytic uremic syndrome ; HUS ; thrombotic microangiopathy ; TMA ; ravulizumab ; complement inhibition therapy ;

Sažetak
Introduction: As the global pandemic continues, new complications of COVID-19 in pediatric population have turned up, one of them being hemolytic uremic syndrome (HUS), a complement- mediated thrombotic microangiopathy (CM-TMA) characterized by triad of thrombocytopenia, microangiopathic hemolytic anemia and acute kidney injury (AKI). With both multisystem inflammatory syndrome in children (MIS-C) and HUS sharing complement dysregulation as one of the key factors, the aim of this case report is to highlight differences between these two conditions and also emphasize the importance of complement blockade as a treatment modality. Case report: We describe a 21-month-old toddler who initially presented with fever and confirmed COVID-19. His condition quickly deteriorated and he developed oliguria, accompanied with diarrhea, vomiting and oral intake intolerance. HUS was suspected, supported with compelling laboratory findings, including decreased platelets count and C3 levels, elevated LDH, urea, serum creatinine and sC5b- 9 and presence of schistocytes in peripheral blood, negative fecal Shiga toxin and normal ADAMTS13 metalloprotease activity. The patient was given C5 complement blocker Ravulizumab and started to display rapid improvement. Conclusion: Although reports of HUS in the setting of COVID-19 continue to pour in, the questions of exact mechanism and similarities to MIS-C remain. Our case for the first time accentuates the use of complement blockade as a valuable treatment option in this scenario. We sincerely believe that reporting on HUS as a complication of COVID-19 in children will give rise to improved diagnosis and treatment, as well as better understanding of both of these intricating diseases.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Profili:

Avatar Url Kristina Vrljičak (autor)

Avatar Url Ivana Vuković Brinar (autor)

Avatar Url Lovro Lamot (autor)

Avatar Url Maja Ban (autor)

Poveznice na cjeloviti tekst rada:

Pristup cjelovitom tekstu rada doi www.frontiersin.org

Citiraj ovu publikaciju:

Matošević, Matija; Kos, Ivanka; Davidović, Maša; Ban, Maja; Matković, Hana; Jakopčić, Ivan; Vuković Brinar, Ivana; Szilágyi, Agnes; Csuka, Dorottya; Sinkovits, György et al.
Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature // Frontiers in pediatrics, 11 (2023), 1092860, 8 doi:10.3389/fped.2023.1092860 (međunarodna recenzija, članak, znanstveni)
Matošević, M., Kos, I., Davidović, M., Ban, M., Matković, H., Jakopčić, I., Vuković Brinar, I., Szilágyi, A., Csuka, D. & Sinkovits, G. (2023) Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature. Frontiers in pediatrics, 11, 1092860, 8 doi:10.3389/fped.2023.1092860.
@article{article, author = {Mato\v{s}evi\'{c}, Matija and Kos, Ivanka and Davidovi\'{c}, Ma\v{s}a and Ban, Maja and Matkovi\'{c}, Hana and Jakop\v{c}i\'{c}, Ivan and Vukovi\'{c} Brinar, Ivana and Szil\'{a}gyi, Agnes and Csuka, Dorottya and Sinkovits, Gy\"{o}rgy and Proh\'{a}szka, Zolt\'{a}n and Vrlji\v{c}ak, Kristina and Lamot, Lovro}, year = {2023}, pages = {8}, DOI = {10.3389/fped.2023.1092860}, chapter = {1092860}, keywords = {Haemolytic uremic syndrome, HUS, thrombotic microangiopathy, TMA, ravulizumab, complement inhibition therapy, }, journal = {Frontiers in pediatrics}, doi = {10.3389/fped.2023.1092860}, volume = {11}, issn = {2296-2360}, title = {Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature}, keyword = {Haemolytic uremic syndrome, HUS, thrombotic microangiopathy, TMA, ravulizumab, complement inhibition therapy, }, chapternumber = {1092860} }
@article{article, author = {Mato\v{s}evi\'{c}, Matija and Kos, Ivanka and Davidovi\'{c}, Ma\v{s}a and Ban, Maja and Matkovi\'{c}, Hana and Jakop\v{c}i\'{c}, Ivan and Vukovi\'{c} Brinar, Ivana and Szil\'{a}gyi, Agnes and Csuka, Dorottya and Sinkovits, Gy\"{o}rgy and Proh\'{a}szka, Zolt\'{a}n and Vrlji\v{c}ak, Kristina and Lamot, Lovro}, year = {2023}, pages = {8}, DOI = {10.3389/fped.2023.1092860}, chapter = {1092860}, keywords = {Haemolytic uremic syndrome, HUS, thrombotic microangiopathy, TMA, ravulizumab, complement inhibition therapy, }, journal = {Frontiers in pediatrics}, doi = {10.3389/fped.2023.1092860}, volume = {11}, issn = {2296-2360}, title = {Hemolytic uremic syndrome in the setting of COVID- 19 successfully treated with complement inhibition therapy: An instructive case report of a previously healthy toddler and review of literature}, keyword = {Haemolytic uremic syndrome, HUS, thrombotic microangiopathy, TMA, ravulizumab, complement inhibition therapy, }, chapternumber = {1092860} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font